Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Study Identifier:
ALXN2040-HV-102
ClinicalTrials.gov Identifier:
NCT05708573
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Rosuvastatin
  • Drug: ALXN2040
Date
Feb 2023 - Mar 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Rosuvastatin
  • Drug: ALXN2040
Date
Feb 2023 - Mar 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.

Trial Locations

Location
Status
Location
Clinical Trial Site
Baltimore, Maryland, United States, 21225
Status
N/A